[
    [
        {
            "time": "2021-10-11",
            "original_text": "晚间重要公告2021年10月11日星期一",
            "features": {
                "keywords": [
                    "公告",
                    "沃森生物",
                    "疫苗",
                    "研发",
                    "生产经营"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "晚间重要公告2021年10月11日星期一",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 1,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-10-11",
            "original_text": "沃森生物：2021年1-6月，公司疫苗产品海外市场收入为5142万元",
            "features": {
                "keywords": [
                    "沃森生物",
                    "疫苗",
                    "海外市场",
                    "收入"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "沃森生物：2021年1-6月，公司疫苗产品海外市场收入为5142万元",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-10-11",
            "original_text": "沃森生物：公司产品研发、生产经营和管理的各项工作均在正常开展",
            "features": {
                "keywords": [
                    "沃森生物",
                    "研发",
                    "生产经营",
                    "管理"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "沃森生物：公司产品研发、生产经营和管理的各项工作均在正常开展",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 4,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-10-11",
            "original_text": "沃森生物：ACYW135群脑膜炎球菌多糖结合疫苗获得Ⅲ期临床试验伦理审查意见书",
            "features": {
                "keywords": [
                    "沃森生物",
                    "疫苗",
                    "Ⅲ期临床",
                    "伦理审查"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "沃森生物：ACYW135群脑膜炎球菌多糖结合疫苗获得Ⅲ期临床试验伦理审查意见书",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-10-11",
            "original_text": "沃森生物最新公告：四价流脑结合疫苗获Ⅲ期临床试验伦理审查意见书",
            "features": {
                "keywords": [
                    "沃森生物",
                    "疫苗",
                    "Ⅲ期临床",
                    "伦理审查"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "沃森生物最新公告：四价流脑结合疫苗获Ⅲ期临床试验伦理审查意见书",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-10-11",
            "original_text": "沃森生物：公司二价HPV疫苗的生产车间已经建设完成",
            "features": {
                "keywords": [
                    "沃森生物",
                    "HPV疫苗",
                    "生产车间"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "沃森生物：公司二价HPV疫苗的生产车间已经建设完成",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-10-11",
            "original_text": "医药行业周报：默沙东新冠药数据公布 腾盛博药递交FDA+EUA申请",
            "features": {
                "keywords": [
                    "医药行业",
                    "默沙东",
                    "新冠药",
                    "腾盛博药",
                    "FDA",
                    "EUA"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业周报：默沙东新冠药数据公布 腾盛博药递交FDA+EUA申请",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-10-08",
            "original_text": "A股融资融券日报：两融余额增加127.02亿元（10月8日）",
            "features": {
                "keywords": [
                    "A股",
                    "融资融券",
                    "两融余额"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "A股融资融券日报：两融余额增加127.02亿元（10月8日）",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 9
            }
        }
    ]
]